Nelde, Alexander
Krumm, Laura http://orcid.org/0000-0002-7926-8661
Arafat, Subhi
Hotter, Benjamin http://orcid.org/0000-0002-5272-9181
Nolte, Christian H. http://orcid.org/0000-0001-5577-1775
Scheitz, Jan F. http://orcid.org/0000-0001-5835-4627
Klammer, Markus G. http://orcid.org/0000-0002-8990-262X
Krämer, Michael http://orcid.org/0000-0002-0310-5903
Scheib, Franziska http://orcid.org/0000-0002-8773-6090
Endres, Matthias http://orcid.org/0000-0001-6520-3720
Meisel, Andreas http://orcid.org/0000-0001-7233-5342
Meisel, Christian http://orcid.org/0000-0003-2984-5480
Funding for this research was provided by:
Charité - Universitätsmedizin Berlin
Article History
Received: 24 April 2023
Revised: 27 September 2023
Accepted: 28 September 2023
First Online: 18 October 2023
Declarations
:
: CM is part of patent applications to detect and predict clinical outcomes and to manage, diagnose, and treat neurological conditions, all of which are outside the submitted work. CHN received research grants from the German Ministry of Research and Education, German Center for Neurodegenerative Diseases, German Center for Cardiovascular Research, and speaker and/or consultation fees from Abbott, Alexion, Astra Zeneca, Bayer Pharma, Bristol-Myers Squibb, Daiichi Sankyo, Novartis, Pfizer Pharma, Portola, and Takeda all outside the submitted work. ME reports grants from Bayer and fees paid to the Charité from Abbott, Amgen, AstraZeneca, Bayer, Boehringer Ingelheim, BMS, Daiichi Sankyo, GSK, Sanofi, Covidien, Novartis, Pfizer, all outside the submitted work. BH reports speaker fees from Pfizer and BMS with no relation to the submitted work. The remaining authors have no conflicts of interest or competing interests to declare. AM received speaker honoraria from Alexion, argenx, Axunio, Boehringer Ingelheim, Bristol-Myers Squibb/Pfizer, Grifols, and Hormosan; honoraria from Alexion, UCB, Janssen, and Merck for consulting services; and financial research support (paid to his institution) from Octapharma, argenx, and Alexion.